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1. Introduction 
Harken et al. had performed the first aortic valve replacement in subcoronary position in 
1960 (Harken, 1960). The “caged ball” valve used in this operation pioneered to the 
prosthetic valves and in the last 50 years many valve types were begun to be used. The early 
and long term results of the patients undergone aortic valve surgery do not depend not only 
the patient-related factors and the type of the surgery. The selected prosthetic valve is one of 
the most important factor affecting survival. According to the analysis of the multicenter 
randomized trials made by Hammermeister et al. involving the recent 15 years, more than 
one third of the deaths among the patients undergone aortic valve surgery were found to be 
related to the prosthetic valve (Hammermeister, 2000). The expectance from an ideal 
prosthetic valve is to correct the present valve pathology, to possess normal functions, to 
normalize patient’s life standards or at least to improve it obviously, and to preserve this 
status during the patient’s lifelong. Additionally, the implantation of the ideal prosthetic 
valve should be easy, the prosthetic valve should be replaced with low mortality and 
morbidity, should not cause a damage to the cardiovascular system, the hospitalization 
period should be short, the valve should be inexpensive (Rahimtoola, 2010). In spite of the 
whole developments in the prosthetic valve technology, the ideal prosthetic valve is not 
found yet, that’s why the task of the surgeon is to select the prosthetic valve not depending 
on the nature of the disease but should be individualized to each patient.  
Nowadays, the replacement alternatives for aortic valve replacement are mechanical valves, 
biological xenograft valves, homograft valves, autograft valves and valves implanted 
transapically or percutaneously which usage has increased in the recent years. Because of 
various advantages and disadvantages, these alternatives are prefered to each other. 
However, for the most appropriate valve choice, each patient should be evaluated 
individually. Additionally, improvements in the drug technology and risk preventing 
measures, due to the deceleration in the development of cardiovascular diseases, the age of 
the operated patients and the surviving period following the operation is increasing 
gradually. Cardiovascular diseases become the most important factor determining the life 
quality and surviving ratio in the elderly population. The main purpose of the aortic valve 
replacement is the improvement of life quality by prolonging the patient’s life (Kolh, 2007; 
www.intechopen.com
 
Aortic Valve Surgery 
 
36 
Thourani, 2008). For that reason, by selecting the most appropriate valve for each patient, 
complications due to the valve can be decreased. Because the rate of the complications of the 
selected valve are affected by the age and comorbidities of the patients.  
Traditionally, the most important criteria for the valve selection is the patient’s age, but with 
the improvements in the production of prosthetic valves and fixation methods, different 
criteria began to come into prominence. Perforations due to the stress or dystrophic 
calcifications are hold to be responsible of the structural degeneration of the biological 
valves (Jameison, 1995). It was shown that the new generation bioprotheses are more 
durable and needed less reoperation in a long period (Silberman, 2008; Potter, 2005; Valfre, 
2006). In addition, improvements achieved in the anticoagulant agents. The superiority of 
the biological valves would be limited by the technology providing patient’s self-monitoring 
of international normalized ratio (INR) (Siebenhofer, 2004) and the development of new 
anticoagulant agents (Salam, 2004). These developments and innovations will be effective in 
the revision of the criteria in the selection of valve. 
Generally, biological valves are preferred in the patients older than the age of 70 years. 
Besides the lower thromboembolic and hemorragic complications incidence at that age, 
durability of biological valves is enough for the survival of patients following aortic valve 
replacement (Cosgrove, 1995; Langley, 1999; Masters, 2004). Additionally, the usage of 
chronic anticoagulation therapy for the biological valves is not necessary as is in the 
mechanical valves. Generally, the mechanical valves which are more durable than the 
biological valves are chosen in the patients younger than the age of 60 years, because of their 
expected longer survival. At that age an early calcification due to the increase of the collagen 
degeneration and increased calcium turnover was seen in the biological valves (Gross, 1998). 
However, the selection of prosthetic valve is more difficult between the age 60 and 70 years. 
The selection of the valve can be easier by paying attention to co-morbidities. Biological 
valves are preferred in the patients with coronary heart disease because of the decrease in 
their expected survival. Additionally, generating less turbulence flow by biological valves 
increases the coronary by-pass graft flow (Hassanein, 2007). When a comparison is made 
between the biological valves, stentless biological valves are seen more advantageous in 
terms of coronary flow reserves. Stentless biological valves are an appropriate choice in the 
patients with left ventricular dysfunction in terms of postoperative recovery (Bakhtiary, 
2006). 
In some patients, the decision of the valve selection is unrelated to the age. Young female 
patients planning to become pregnant is a special patient group. In these patients, with the 
avoidance of an anticoagulation therapy during the pregnancy via biological valve 
replacement (De Santo, 2005), in experienced centers Ross procedure is offered as an 
alternative therapy (Bonow, 2008). Additionally, it is suggested that not only the mechanical 
prosthetic valves or anticoagulant agent usage, but at the same time the acceleration of the 
structural degeneration of biological valves is an important issue needed to be avoided 
during the pregnancy (Jamieson, 1988).  
The pulmonary autograft procedure in patient with aortic valve disease is an alternative to 
the prosthetic valves and the aortic allograft. This technique was introduced in 1967 by 
Donald Ross (Ross, 1967). The benefits of the Ross procedure are the superior durability of 
the pulmonary autograft when compared to biological valves in the aortic position, the 
growth potential of the autograft, and avoidance of prolonged anticoagulation (Akhyari, 
2009). Hence, this procedure is primarily used in young or growing patients. 
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Additionally, some factors provide making a decision on the valve selection regardless of 
the patient’s age. In case of previous thromboembolism history, chronic atrial fibrillation, 
low ejection fraction, previously implanted valve type and intracardiac thrombus, the selection 
of the valve is made regardless of the patient’s age. The replacement of mechanical prosthetic 
valves is not appropriate in the patients with low sociocultural level, exposed to frequent 
traumas due to occupational reasons, predisposed to bleeding, unwilling to use or is 
contraindicated to use anticoagulants. Biological valve options are good alternatives in these 
patients. In patients with small ventricle, when mitral valve replacement and aortic valve 
replacement are needed to be done together, and the usage of mechanical prosthesis is not 
appropriate due to their high profile, biological valves have to be selected for replacement. 
These prosthetic valves are similar according to the perioperative mortality and immediate 
and long term survival (Silberman, 2008). These similar results have been shown not only 
for the elderly patients but also for middle aged patients (Carrier, 2001; Khan, 2001). But, 
during the biological valve replacement cardiopulmonary bypass time and ischemic time 
are longer than in those with mechanical valve replacement (Silberman, 2008) and especially 
stentless biologic valve implantation is more difficult in technical aspect. Thus, surgical 
experience and how the patients will be affected from the longer operation time are the 
other factors should be considered. The fact that stentless biological valves have 
hemodynamic advantages (Silberman, 2001), possibility of a replacement of larger sized 
prosthesis (Del Rizzo, 1994), better durability (Bach, 2005) and long term survival ratios 
(Albertucci, 1994; Westaby, 2000) in comparison with the stented biological valves, provides 
their preference in the young patients. The advantages of Ross procedure with respect to 
postoperative survival, life quality and reoperation requirement in adult patients undergone 
homograft and autograft aortic root replacement will provide it becoming widespread 
(Hammermeister, 2000; Stassano, 2009; El-Hamamsy, 2010). 
Transcatheter aortic valve implantation (TAVI) recently developed and commonly used in 
some centers as a good alternative technique for the patients in whom the aortic valve 
replacement is with high risk (Cribier, 2006; Webb, 2007; Walther, 2007, Rode’s-Cabau, 
2010). In these patients, surgeon has to choose optimal valve and obtain the largest 
prosthetic valve area. TAVI has excellent hemodynamic performance. In the patients who 
had myocardial dysfunction, apoptosis of the cardiomyocites triggered by the ischemia, 
oxidative stress and inflammatory injury during the open heart surgery, could retard the 
postoperative recovery and improvement of myocardial functions (Anselmi, 2004, Vahasilta, 
2005). In these risky patients, TAVI could protect the myocardial functions and LVEF can be 
increased after the intervention (Webb, 2007; Bauer, 2004; Clavel, 2009). 
It was offered to choose mechanical valves in patients having chronic renal disease because 
of earlier degeneration by rapid calcification of biological valves. But, in ACC/AHA 
guideline updated in 2006, there is no recommendation for the choice of prosthetic valve 
type for these patients. Probably, this revision depends on new studies claimed similar 
results for both mechanical and biological prosthetic valve types for the patients on dialysis 
(Lucke, 1997; Kaplon, 2000; Herzog, 2002; Brinkman, 2002; Bonow, 2006). After these results, 
the criteria for the choice of valve type in the patients on dialysis shifted as those in patients 
without on dialysis. With holding intact parathormon, calcium, and phosphor levels at 
optimal levels, not only early degeneration of biological valves can be prevented but also the 
survival the patients on dialysis can be increased (Kazama, 2007; Kimata, 2007; Nakai, 2008). 
Degeneration of new generation biological valves has decreased in dialysis patients as in 
those non-dialysis patients with the technological improvements (Brinkman, 2002). 
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Because of the high mortality ratio after aortic valve replacement, measures should be taken 
for the prevention of infective endocarditis. Although, infective endocarditis risk after 
mechanical and biological valve replacement is similar in both prosthetic valve types, in case 
of a need for aortic valve replacement in a patient with infective endocarditis, allografts 
have advantages with respect to resistance to active endocarditis. But it is difficult to obtain 
allografts at any time and the valve durability depends on donor age, time after explantation 
from donor, and host immunologic response (Yacoup, 1995; Takkenberg 2002).  
There are few prospective, randomized studies comparing the valve types used in aortic 
valve replacement. Besides, the valve types compared in these studies are limited. Large 
studies comparing all the prosthetic valves the autografts, mechanic valves, xenograft tissue 
valves will be helpful for the optimal prosthetic valve choice.  
Because, the increase of durability for new generation biological valves and the decrease of 
the elective operations risk by the improvements of surgical techniques, the biological 
valves will be used widespread in the younger patients (Silberman, 2008; Bonow, 2006). We 
have to present this option to patients. Thus, the patients could join the decision process for 
the choice of the prosthetic valve type. Additionally, the patient’s should learn the 
frequency of coagulation monitorization, the possibility for disturbed mechanical valve 
sound, hemorrhagic complications by using mechanical valve and reoperation caused by the 
structural degeneration for the biological valves. 
In the patients planning to undergo aortic valve replacement, not only the patient’s age but 
also patient’s life expectancy, coagulopathy, life-style, occupation, comorbidities, anticoagulant 
therapy contraindication, surgeon’s experience should be reviewed for the choice of the 
most appropriate prosthetic valve type for each person (Silberman, 2008 ). In this way, the 
best survival and improved life quality can be offered to the patient. 
The factors should be kept in mind which will be given in details below: 
• Patient’s age 
• Comorbidities 
• Chronic atrial fibrillation 
• Chronic renal failure 
• Malignancies 
• Small aortic annulus 
• Other valve diseases 
• Aortic dilatation 
• Active infective endocarditis 
• Young women 
• Pregnancy 
• Redo valve surgery 
2. Patient’s age  
Biologic or mechanical aortic valve prostheses have been widely used in patients with aortic 
valve disease. The choice of prostheses remains controversial due to the higher rate of 
structural dysfunction with bioprosthesis and due to the risk of thromboembolism or 
hemorrhage releated to the anticoagulation treatment of a mechanical prosthesis. The 
elderly population is increasing due to increase in the human life span. Thus cardiac surgery 
is increasing in the elderly. In elderly patients with aortic valve replacement, early and long-
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term results have significantly improved due to technical optimization, better myocardial 
protection and postoperative management. In studies, the term elderly is often used to 
describe different population. Some researchers define elderly population as older than 70 
years (Tseng, 1997), whereas others define elderly as being older than 65 years (Florath, 
2005). Structural failure of bioprostheses are strongly related to the patient’s age at valve 
insertion (Akins, 1998). Bioprostheses have a significantly higher rate of reoperation. 
Freedom from reoperation for bioprostheses is >95% at 5 years, >90% at 10 years, but <70% 
at 15 years. However freedom from reoperation for mechanical valves is >95% at 5 years 
and >90% at 15 years (Desai, 2008). Many cardiac surgeons opt patient age 70 years or older 
as a routine age for insertion of bioprostheses. Several studies have compared stentless and 
stented aortic valve bioprosthesis. Stentless aortic bioprostheses were shown to be 
hemodynamically superior to stented aortic bioprostheses (Borger, 2005; Walther 1999). 
Stentless aortic bioprostheses provide a larger effective orifice area and lower transvalvular 
gradients postoperatively because of the absence of a sewing ring and stent. However the 
implantation of the stentless valve is more difficult and is generally associated with longer 
myocardial ischemic time and may therefore have a higher perioperative complication rates 
(Borger, 2005). Choice of mechanical aortic prostheses in elderly patients is often due to 
different factors, including the use of anticoagulation for other diseases, less need of 
reoperation and preference of the patient or surgeon. In patients younger than 60 years of 
age, mechanical prosthesis is recommended because of prosthesis durability (Emery, 2005; 
Carrier, 2001). In the age between 60 and 70 years, other individual factors have to be taken 
into account.  
Transcatheter aortic valve implantation has become a clinical reality, applied to high-risk 
patients who are elderly or not operative candidates. TAVI has been developed as an 
endovascular alternative to surgical aortic valve replacement. This technique is performed 
with transfemoral or transapical routes. Successful implantation rate has been found 
between 85% and 100% (Al-Attar, 2009; Johansson, 2011).  
Homografts and autologous pulmonary valves are good alternatives for infants and 
childhood patients. In this method advantages like the growing ability, perfect durability, 
avoidance of prolonged anticoagulation, excellent hemodynamic performance, low 
transvalvar pressure gradient, large effective orifice area of pulmonary autologous valve are 
shown (Alsoufi, 2009; Gatzoulis, 1999). Complications like neoaortic failure seen in the 
postoperative period has decreased following the improvements in the implantation 
techniques of autologous pulmonary valves (David, 2000; Takkenberg, 2006), and 
pulmonary allograft stenosis has decreased due to appropriate usage of anti-inflammatory 
agents (Carr-White, 2001; Raanani, 2000). For that reason while the usage of aortic route 
replacement and Ross procedure are getting widespread, on the other hand it is suggested 
that in case of usage of pulmonary autograft the operation is complex and while during the 
repair of one valve pathology, two valves are jeopardized (Alexiou, 2000). It is suggested 
that in the childhood, metallic valves are good alternatives to Ross procedure because of 
their quite easier implantation, their perfect durability and hemodynamic performance 
(Alexiou, 2000). In the literature, late period thromboembolism and hemorrhagic 
complications following mechanical valve replacement in the childhood are reported in a 
quite low rates (Ibrahim, 1994; Champsaur, 1997; Mazzitelli, 1998; Lupinetti, 1997). The most 
important disadvantage of the mechanical valves in the childhood is the requirement of 
replacement of them with bigger size later. However, in a great majority of the childhood 
patients adult sized mechanical valve replacement is possible with aortoplasty technique 
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(Nicks, 1970). Thus, it is suggested that in this age group mechanical prosthetic valves are 
good alternatives of biological ones. Another alternative to Ross procedure are allografts. 
Allograft aortic valves do not vary in the early and late period due to hemodynamic respect 
(Lupinetti, 2003).  
3. Comorbidities 
Atrial fibrillation is the most common arrhythmia in patients undergoing aortic valve 
surgery (Ngaage, 2006). Many studies show that atrial fibrillation is a risk factor for 
decreased long-term survival (Vidaillet, 2002; Stewart, 2002). Loss of synchronous 
atrioventricular contraction results in ventricular dysfunction or congestive heart failure. 
The Framingham Study shows that stasis of blood flow in the left atrium, three- to five fold 
increases risk of stroke in a patient with atrial fibrillation (Wolf, 1991). Currently, 
acetylsalicylic acid and warfarin are approved antithrombotic agents for stroke prevention 
in patients with atrial fibrillation. However randomized trials are shown that antiplatelet 
agents are less effective than anticoagulant agents (Hart, 1999). It seems that first choice is 
mechanical aortic valve because of the need anticoagulant therapy in patients with chronic 
atrial fibrillation undergoing aortic valve surgery. Nevertheless an old patient more than 60 
to 65 years who has atrial fibrillation may be preferable to insert a biologic aortic valve due 
to an increased risk of bleeding with anticoagulant therapy (Rahimtoola, 2003). If bleeding 
obliges discontinuing anticoagulant therapy, then this is a risk of thrombosis in patient with 
mechanical aortic valve.  
Patients with chronic renal failure have a poor long-term survival secondary to their 
underlying renal disease. Four-year survival of patients on hemodialysis or peritoneal 
dialysis, regardless of whether they undergo valve replacement, is approximately 40% 
(Brinkman, 2002). Chronic renal failure is also a significant risk factor for increased 
morbidity and mortality in patients undergoing cardiac surgery (Kogan, 2008). Chronic 
uremia, hypertension, hyperlipidemia and increased calcium phosphate product associated 
with secondary hyperparathyroidism predispose to cardiac valvular abnormalities in 
patients with chronic renal failure. Early studies on biologic valve implantation in these 
patients show accelerated calcification of bioprosthetic valves (Lamberti, 1978; Monson, 
1980). Therefore, mechanical valves were recommended by the ACC/AHA in patient with 
chronic renal failure and the guideline considered the use of biologic valves potentially 
harmful. (Bonow, 1998). However, current studies demonstrated that no significant  
survival difference between mechanical and bilologic valves (Brinkman, 2002; Thourani, 
2011). Furthermore, several studies recommend biological valve instead of mechanical valve 
in patients on chronic dialysis (Lucke, 1997). Chronic renal failure is a known major risk 
factor for bleeding in patients with anticoagulant therapy (Lanefeld, 1989). These patients 
have also a increased risk of endocarditis due to frequent vascular access and impaired 
immunity (Chan, 2006). The type of aortic valve chosen for these patients should be 
individualized to the age of the patient and expected long-term survival. Older and patients 
with relative short life expectancy should be considered as candidates for biological aortic 
valve.  
Malignant tumors is another comorbidity in patients undergoing aortic valve replacement. 
Currently there is no specific study investigating effects of the type of aortic valve 
prostheses on survival in these patients. However analyses revealed that the presence of a 
malignant tumor was an independent risk factor on survival after cardiac surgery (Mistiaen, 
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2004). Life expectancy of the patient who has malignancy has to be considered on decision 
for choice of prosthetic aortic valve. Biological aortic valve may be a good choice if life 
expectancy is about five years or less in patients with malignancy (Rahimtoola, 2010).  
Aortic valve replacement is an effective therapy for patients with aortic valve pathologies, 
however, transvalvular gradient is almost always higher than the physiologic gradients of 
the aortic valve. This gradient is related to the valve size and body surface area. Severe 
patient-prosthesis mismatch have been found to be associated with increased early and late 
mortality (Rao, 2000). Aortic root enlargement procedures are an option in patients with 
small aortic root. However, these techniques have been found to be associated with 
prolonged myocardial ischemia and perioperative bleeding which is frequently seen in the 
elderly patients (Kunihara, 2006). Stentless biologic aortic valves or homografts seem like 
good choice for patients with small aortic root size at risk for patients-prosthesis mismatch 
(Bonow 2008). Subcoronary implantation of stentless bioprostheses has been associated with 
residual transvalvular gradients (Milano, 2001). Kunihara and colleagues showed that full 
aortic root replacement using a stentless aortic bioprostheses may be advantageous in 
patients with small aortic root (Kunihara, 2006). Transcatheter aortic valve implantation 
may be an alternative to prevent patient-prosthesis mismatch in high-risk patients 
(Jilaihawi, 2010). Moderate patient-prosthesis mismatch is generally well tolerated in elderly 
patients who have small aortic root (Takaseya, 2007). However, the effect of patient-
prosthesis mismatch is more important in younger patients. New generation mechanical 
aortic valve which design to increase orifice area by modifying the outside geometry of the 
orifice housing may be an option in younger patients with small aortic root (Bach, 2002). 
Additionally, mechanical aortic valves which can be implanted supraannular position may 
be preferable in younger patients with small aortic root (Roedler, 2008). Pulmonic valve 
autotransplantation may be preferred to prevent patient-prosthesis mismatch and allow 
growth of the autograft in children (Bonow 2008). Root enlargement techniques should be 
considered in younger patients when a severe patient-prosthesis mismatch can not be 
avoided with these models of prostheses. 
Whether bioprosthesis or mechanical valve in simultaneous aortic and mitral valve surgery 
will be associated with a better result remains under debate. There is no specific 
recommendation for surgical strategy of multiple valve disease in ACC/AHA practice 
guideline (Bonow, 2008). Caus and colleagues reported that the rate of reoperative mortality 
was significantly higher in patients >65 years who had double valve replacement (Caus, 
1999). Hence, some surgeons recommend mechanical valves for the majority of patients in 
double valve replacement (Urban, 2011). However, a cohort study of 1057 patients showed 
that biologic valves have the best in-hospital and long-term survival in patient ≥70 years 
undergoing concomitant aortic and mitral valve replacement (Leavitt, 2009). 
Composite graft replacement of the aortic root is a favored technique in dilatation of the 
ascending aorta associated with aortic valve pathologies. It is more complex than isolated 
aortic valve replacement. Replacement of the aortic valve and the ascending aorta with a 
conduit consisting of a mechanical valve and a dacron tube is generally preferred procedure. 
This technique has been described by Bentall and Debono in 1968 (Bentall H, 1968) and it 
has led to increased life expectancy for patients with Marfan syndrome. In spite of initial 
mortality risk is higher, long term survival has been found similar to aortic valve 
replacement in patients with composite mechanical valve-graft conduit aortic root 
replacement (Kalkat, 2007). Homografts and conduits consisting of a stented or stentless 
xenograft valve may be the choice especially in elderly or in patients with endocarditis. 
www.intechopen.com
 
Aortic Valve Surgery 
 
42 
Other option is pulmonary autograft for aortic root replacement. In the study of Akhyari 
and colleagues, pulmonary autograft had no advantages over composite grafts regarding 
mid-term morbidity and mortality in aortic position (Akhyari, 2009).  
4. Active infective endocarditis 
Despite advances in the diagnosis and antibiotic treatment of infective endocarditis, aortic 
valve endocarditis is most commonly treated surgically by valve replacement in 
combination with antibiotics. For patients with aortic valve endocarditis, the choice of valve 
between bioprostheses, homografts and mechanical prostheses remains controversial. 
According to the ACC/AHA guidelines for management of patients with heart valve 
disease, valve repair should be preferred because of the risk of infection of prosthetic 
materials in patients with native valve endocarditis (Bonow, 2006). There is no specific 
recommendation for use of particular valve prosthesis. In a randomized study, patients with 
aortic valve endocarditis recieving bioprostheses have been found lower 5-year survival rate 
than patients recieving mechanical valves and it has been found no difference between 
patients receiving homografts and mechanical valves (Nguyen, 2010). Wos and colleagues 
showed that the risk of recurrent endocarditis was higher with bioprostheses than with 
mechanical valves (Wos, 1996). Guerra et al also found that the risk of endocarditis 
reinfection is very low with mechanical valves (Guerra, 2001). Homograft seems to be good 
choice in severe destructive prosthetic (Musci, 2010) or native (Klieverik, 2009) valve 
endocarditis with aorto-ventricular dehiscence caused by abscess. Petterson et al reported 
that the Ross operation is an attractive option in patients with aortic valve endocarditis in all 
age (Petterson, 1998). 
5. Prosthetic valve choice in prengnancy 
Native valve diseases and prosthetic valve disfunction are still the most important surgical 
indications in pregnant women requiring heart surgery (Weiss, 1998). Aortic valve diseases 
can become more symptomatic during pregnancy. A serious aortic stenosis is seen relatively 
rare in pregnancy. While transvalvular gradient is below 50 mmHg the possibility of heart 
failure during the pregnancy and delivery is low (Oakley, 2003). In case of aortic stenosis, 
fetal prognosis due to growth retardation, early delivery or low birth weight is deteriorated 
(Hameed, 2001; Malhotra 2004). For that reason, in case of asypmtomatic aortic stenosis, 
with an intervention before pregnancy the becoming the situation more complex can be 
prevented. As long as left ventricular sistolic function is not impaired aortic insufficiency 
can be well tolerated during pregnancy. On the other hand severe heart insufficiency can 
develop in patients with acute aortic failure or low EF (Oakley, 2003). There is not enough 
experience about the implementation of balloon aortic valvuloplasty during pregnancy. 
Furthermore, a permanent solution is not provided with this approach (Siu, 1997). However, 
these approaches can be used as a bridge before the delivery because of the maternal and 
fetal mortality risk due to serious aortic stenosis and if it is required, a surgical intervention 
can be applied after the delivery.  
It was reported that in case of a development of a valve trombosis during pregnancy in 
patients with a previous mechanical valve replacement a replacement can be prevented with 
the addition of trombolytic treatment. However, it has to be known that some complications 
can be seen with the trombolytic treatment, the success rate is limited, recurrences can be 
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seen after the treatment (Elkayam2005; Roudaut 2003). As the data about this topic is limited 
the complication rates seen in nonpregnant patients can be taken into consideration. A 
surgical treatment during pregnancy can be required in patients without benefits despite 
medical treatments and percutaneous approaches. Although the maternal mortality is below 
3% for pregnant patients undergoing CPB with aortic valve replacement, fetal loss reaches 
20% (Pomini 1996). Some strategies like avoiding hypotermia, providing enough perfusion 
pressure are recommended in order to decrease these adverse effects of CPB. Besides that, 
because of the effects of cardioplegia usage like hemodilution and hyperkalemia, recently 
some valve operation in beating heart also are reported (Tehrani 2004). The choice of valve 
type for valve replacement in pregnancy is similar to the choice criteria in young women 
patients. In a similar way it is difficult to make a decision about the valve choice because of 
the degeneration risk of the biological valves in young women and the requirement of 
anticoagulation for the mechanical valves, the fact that the trombosis of the mechanical valves 
during pregnancy can be a cause of mortality, and the limited data about how the homografts 
are influenced during pregnancy. However, the participation of the patient in the decision 
process has to be provided by discussing with the pregnant patient and informating her for 
all of the possible complications and frequencies. During the decision besides the current 
pregnancy, the expectation of a new pregnacy in future is also important (Elkayam2005). On 
the contrary to the results of the previous studies, recent studies have demonstrated that 
pregnancy does not cause a deterioration or calcification in biological valves (Reimold 2003).  
6. Prosthetic valve choice in young women 
Especially in the developing countries valve diseases requiring a surical intervention is seen 
frequently in young age group due to the fact that rheumatic valve diseases are not very 
uncommon. Although the valve repairement is the most ideal treatment method in young 
age group, in case of a serious impaired structure of the valve a repairement is not always 
possible. In that situation valve replacement is needed. A prothesis choice is still a 
controverisal issue in young patients needing prosthetic valve replacement (Solymar 1991; 
Trimn 2007). The reason is that all of the chosed prosthetic valves have their own 
advantages and disadvantages. That’s why the decision has to be made according to the 
most suitable valve alternative for the patients’ characteristics. The patient has to be 
informed about the advantages and disadvantages of the valve types in terms of possible 
complications. Thereafter, the patient has to be involved in the decision process. Young 
women have a different situation among the patients undergoing valve surgery because of 
the pregnancy possibility. The fact that the bioprothesis used in young age can be exposed 
to early degeneration because of the rapid body metabolism or the requirement of 
anticoagulants in patients with preference of mechanical prosthetic valves are situations 
which have to be evaluated seperately. As the valve lesion present before pregnancy will 
become more pronounced with the pregnancy, patients can undergo a comfortable period 
during the pregnancy with the intervention to the valve lesion in that period. In these 
approaches, along with the medical treatment support, when required, balloon-plasty is the 
first preference. By postponding of the sugical interventions during the pregnancy, maternal 
and fatal risk due to the surgery is tried to be prevented. Yet if there is no benefit although 
the applied medical treatment and percutaneous intervention, valve repairment or valve 
replacement is applied surgically. The main difficulty in that stage is the choice of the valve 
type which will be used.  
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The biological grafts include heterografts, homografts and autografts. Among these 
prothesis, maximal clinical data exists about the porcine heterografts. Biological valves 
undergo some degeneration in every age and for that reason their long-term durability is 
influenced which results in a higher rate of valve reoperation (Brais 1985; Jamieson 2003; 
Gross 1998). In young patients this degeneration is seen more frequently because of the 
increased calcium turnover, fatigue-induced lesions and collagen degeneration, and discrete 
immunologic reaction (Berrebi 2001; Gross 1998; Salazar 1999; Badduke 1991; Sbarouni 
1994). Additionally, in some studies it was suggested that the usage of biological valves in 
early periods results in increased rate of degeneration in pregnancy. Besides that, there are 
also studies demonstrating that the biological valves are not damaged during pregnancy 
due to the developments in the fixation technics of the first generation biological valves and 
the valve production technology (Jamieson 1995; North 1999; Salazar 1999). Interestingly, in 
a study showing that bioprosthesis are more rapidly degenerated during pregnancy, the 
survey rate of the patients with mechanical valves were found to be lower than those with 
biological valves (Robyn 1999). These rates were reported to be influenced by the pregnancy 
rate after the biological valve replacement (Lee 1994). The controversial results in different 
studies can be influenced by some factors like the inclusion of non-homogeneous 
populations, disregard of the age of patients, the time period between prosthesis 
implantation and gestation, and the condition of the prothesis before pregnancy, which 
avoids the correct evaluation of the data. Additionally, data about long-term follow up, 
especially in case of repeated pregnancies, is also unsufficient. Althougt there is no 
consensus about the influence of the pregnancy on biological valve degeneration, this 
possibility has to be told to the potential pregnant patient. The reason is that re-replacement 
is needed for the patients with degenerated biological valves. Especially the risks of such 
operations during pregnancy in terms of maternal and fetal prognosis has to be denoted. 
Fifty percent of the patients who undergone biological valve replacement in young age 
require a reoperation 10 years later. It means that almost all of these patients will undergo at 
least one re-operation during their life period (Elkayam 2005). The mortality rate following 
such a re-operation is reported as 3.8-8.7% (Jamieson 1995; Badduke 1991). Shaer et al. 
showed in their 18 years follow-up study that pregnancy has no additive contribution to the 
structural degeneration of biological valves. The importance of that study is that all of the 
patients included in the study have similar characteristic features (Fayez 2005). In studies 
comparing two different type heterografts used in young patients (Hancock and Carpentier-
Edwards porcine bioprostheses), a structural valve deterioration in a rate of 50-70% in 10 
years follow-up was demonstrated (Yum 1995; Jamieson 1988). Similarly, North et al. 
reported that structural valve deterioration in 10 years follow-up can be seen in high rates as 
82% [preg9/5]. As it is seen the valve choice influences not only the possible complications 
but also the patient’s survival. In a recent study about the usage of the last generation 
biological valves in young patients, it was shown that the valve degeneration is quite low 
and survival rates are distinctly high. These good results are suggested to be due to the 
usage of new fixation technics and the development of agents used for anti-mineralization 
(Carpentier 1995). 
The biological valves are less thrombogenic than the mechanical valves. For that reason 
anticoagulation is not needed. However, tromboembolic complications due to biological 
valves, although rarely, are seen. They can be seen especially in the first days following 
valve replacement before the development of an endothelization. The annual tromboembolism 
risk following biological valve replacement is 0.7% (North 1999). 
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Patients using mechanical valves can feel uncomfortable because of the valve sounds, are 
more frequently asked to come for outpatient visits and need more closed monitorization 
with blood tests. Besides that, the mechanical prosthetic valves are not degenerated by time. 
The usage of anticoagulants is essential. Some physiological changes are seen with 
pregnancy. Fibrinogen level can increase and reach to two folds levels than normally. As 
factors VII, VIII, IX, and XII are increasing in the third trimestre, antritrombin II level is 
decreasing. Duration of pregnancy, body composition and rapid fluid shifts were 
demonstrated as factors influencing the coagulation system. Blood volume, viscosity, 
intraabdominal pressure increase and venous compression also increases (Al-Lawati AA, 
2002). As there is a presence of naturally hypercoagulable state the dose of the anticoagulant 
treatment should be kept higher. The rate of mechanical valve trombosis reaches 14% 
because of this hypercoagulable state (Abbas, 2005). A maternal mortality rate of 10% is seen 
in these patients (Weiss BM, 1998). On the other hand, complications due to high dose 
anticoagulants is seen more frequently too. The superiority of the biological valves was 
emphasized in the retrospective evaluations of the first generation mechanicalal valves in 
order to avoid the complications due to high dose anticoagulants (Jamieson, 1993; 
Cannegieter, 1994). However, the tendency to trombosis of the mechanicalal prosthetic 
valves in that period was higher. 
With the development of a new generation of mechanical valves, optimal anticoagulation 
doses were provided too. However, the usage of anticoagulants during pregnancy is still a 
controversial issue. Actually, as a common practice, after heparin usage in the first 
tremestre, warfarin treatment is used up to the expected delivery time, and then heparin is 
used instead again. Although there are centers accepting this procedure reliable, this subject 
is still a controversial subject because of the present complications (Salazar, 1996; Ismail, 
1986; Pavankumar; 1988). For that reason there is no distinct concensus about the ideal 
anticoagulant treatment in terms of maternal and fetal prognosis. Warfarin is a good 
anticoagulant. But as it can pass placenta, fetal malformation, fetal loss and peripartum 
haemorrage can be seen in the organogenesis stage. These effects of warfarin were shown to 
be dose dependent [Oakley, 2003; Hanania, 2001). Although it is shown that when a 5 mg 
dose was not exceeded it is not a cause of embriopathy, it is known that it increases the rates 
of abortus. For that reason it is suggested that the embriopathy rates seen in the live births is 
relatively lower. Especially because of embriopathy occurring with warfarin usage between 
6 and 12 weeks, a shifting heparin treatment is offered in this period (Iturbe-Alessio; 1986). 
As heparin is a large molecule and can not pass the placenta, negative effects on fetus is not 
expected. Additionally, heparin was not found to be associated with bleeding during the 
peripartum period (Noller, 1982; Iturbe-Alessio; 1986). For that reason warfarin treatment 
should be replaced with heparin treatment in the post 36 week period. A mortality rate of 1-
4% is seen in the pregnant patients with mechanicalal prosthetic valves, which is more 
commonly due to valve thrombosis (Chan, 2000; Elkayam, 2005) The usage of heparin 
during pregnancy was shown to be a cause of maternal tromboemboli states like occlusive 
prosthetic thrombosis, including fatal events (Sbarouni, 1994; Hanania, 1994; Salazar, 1996; 
Oakley, 2003). The usage of low molecule weight heparins is not recommended in the 
pregnancy period because of the difficulty in their monitorization and titration, and their 
close relationship with the tromboembolic events (Iturbe-Alessio, 1986; Salazar, 1996; 
Meschengieser 1999). Although under current conditions warfarin seems to be more 
appropriate treatment method because of the reduction in maternal complications, most 
female patients, when they are informed, do not want to use this drug because of its fetal 
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effects. Moreover, even in the second trimestre, they do not want to stop heparin and go on 
with heparin treatment (Evans, 1997; Yinon, 2009) 
Yinon et al. evaluated the usage of low molecule weight heparin and aspirin in patients with 
mechanicalal prosthetic valve replacement who do not want to use warfarin during 
pregnancy because of its embriopathy risk. The study reported that even in patients 
followed-up with carefull monitorization the rate of the maternal cardiac and fetal 
complications is high and bleeding is seen (Yinon, 2009). Additionally, non-cardiac 
complication rates like postpartum bleeding was found to be as high as 13%, which is higher 
than it is reported in the previous studies.  
In order to avoid these possible complications the effect of the anticoagulation therapy 
during pregnancy has to be closely monitorized. It is important to identify the most 
important strategy by transition between warfarin and heparin in the distinct periods of 
pregnancy.  
Homografts can be an alternative for the young women at childbearing age. There is no 
evident data about the possible complications of this valve not needing an anticoagulation 
and its generation during pregnancy (Yacoub, 1995; Waszyrowski, 1997). However, some 
studies in the literature gave an idea. Robyn et al. showed that less degeneration is seen after 
the usage of homograft in comparison with biological prosthetic valve users and less 
requirement of reoperation is needed (Robyn 1999). Similarly, North et al. reported in a 
recent study that homografts are more resistant in comparison with bioprosthetic valves in 
10 years follow-up and structural valve detorioration is developed more infrequently (72% 
vs. 18% ) (North 1999). It was shown that there was less structural failure requiring 
reoperation in homografts in comparison with biological grafts (Yum, 1995; Jamieson, 1988). 
Studies evaluating the effects of pregnancy on homografts are even more limited. Sadler et 
al. reported that 94% live births had eventuated in patients followed-up following 
homograft valve replacement and only in two patients a heart failure developed during 
pregnancy (Sadler, 2000). Although there are studies supporting these results, data about 
how the homograft are effected during pregnancy is still limited (Dyke, 2003). Prospective 
studies in future can suggest homografts as appropriate alternatives in young women.  
Especially for young women who wants to get pregnant Ross procedure can be a good 
alternative because its perfect valve hemodynamics and not being thrombogenic [Al-Halees, 
2002). However this opertaion is difficult in terms of technical aspect and as the operative 
mortality is reported as 2-13% in different studies it has to be performed in experienced 
centres (Rahimtoola, 2003; Takkenberg, 2002; Schmidtke 2003). Additionally, the effects of 
pregnancy on Ross procedure in not clear, as for homografts (Schmidtke, 2003; Dore,1997; 
Martin, 2003). Dore and Somerville (Dore,1997) reported in their study made with small 
number of patients that serious complications like mortality, trombo-embolic event or 
bleeding was not observed in patients who underwent Ross procedure. But, as there is not 
enough data for this surgical technique, its usage in young women who have potential for 
becoming pregnant is not still widespread. 
As a conclusion, the optimal prosthetic cardiac valve for the women at childbearing age is 
still a controversial subject. The reason is that there is no consensus about the effects of 
anticoagulants and side effects in the research studies. The degenerative effects of biological 
valves on pregnancy is not clearly known. There are studies showing the effects of 
trombolytic studies even in trombosis of mechanicalal prosthetic valves. The reoperation 
carried out after the degeneration of biological valves was reported to be more safely 
performed. As it is seen, these study results give different messages. For that reason, in a 
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process of making a choice for the prosthetic valve, a comparison should be made according 
to the degeneration risk of biological valves, tromboemboli due to mechanicalal prosthetic 
valves and bleeding complications due to anticoagulants. In summary, every patient has to 
be evaluated individually in order to make a desicion what is the best for her or him. 
(Mihaljevic, 2005). All of these results should be shared with the patient before the 
operation. 
6.1 A valve selection for the reoperation 
Sometimes a valve replacement because of valvular or non-valvular reasons is needed to be 
performed again. A valve replacement is made because of different reasons like the valve 
degeneration, calcification or valve thrombosis of the previously replaced prosthetic valve, 
endocarditis, dehicence, or pannus formation. In that situation, the selection of the 
prosthetic valve needed for the replacement should be made according to the individual 
characteristics. When in case of active prosthetic valve endocarditis tissue valve more 
resistant to infection is selected, age factor should be taken into consideration too. Especially 
a rapid degeneration in a patient with previously selected biological valve can be a 
cautionary signal that this situation can be eventuated again. A comprehensive information 
about the both prosthetic valve types should be given to the patient before the reoperation. 
Thereafter, the final decision about the valve choice should be taken together with the 
patient. 
Recently developed percutaneous aortic valve replacement can also be appropriate 
alternative for the reoperation. Especially it is an appropriate alternative for the patients in 
whom the reoperation is riskly because of comorbid situations (Fusari, 2009). With this new 
approach called as “valve-in-valve”, trans-catheter stent valve is implanted percutaneously 
in the degenerated biological valve. The early results of this tecnique are promissing, but the 
long period results are not still known [Gotzmann, 2011, Fusari, 2009, Ye, 2007). At the same 
time, it should not be forgotten that complications like occlusion of the coronary ostiums, 
endocarditis, embolization of the prosthesis, iatrogenic aortic dissection can be seen (Tay, 
2011; Kukucka, 2011; Carnero-Alcázar 2010). 
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